177 related articles for article (PubMed ID: 24586660)
1. Small molecule inhibitors target the tissue transglutaminase and fibronectin interaction.
Yakubov B; Chen L; Belkin AM; Zhang S; Chelladurai B; Zhang ZY; Matei D
PLoS One; 2014; 9(2):e89285. PubMed ID: 24586660
[TBL] [Abstract][Full Text] [Related]
2. Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin.
Sima LE; Yakubov B; Zhang S; Condello S; Grigorescu AA; Nwani NG; Chen L; Schiltz GE; Arvanitis C; Zhang ZY; Matei D
Mol Cancer Ther; 2019 Jun; 18(6):1057-1068. PubMed ID: 31015308
[TBL] [Abstract][Full Text] [Related]
3. Targeting ovarian tumor cell adhesion mediated by tissue transglutaminase.
Khanna M; Chelladurai B; Gavini A; Li L; Shao M; Courtney D; Turchi JJ; Matei D; Meroueh S
Mol Cancer Ther; 2011 Apr; 10(4):626-36. PubMed ID: 21330459
[TBL] [Abstract][Full Text] [Related]
4. Mapping the minimum domain of the fibronectin binding site on transglutaminase 2 (TG2) and its importance in mediating signaling, adhesion, and migration in TG2-expressing cells.
Soluri MF; Boccafoschi F; Cotella D; Moro L; Forestieri G; Autiero I; Cavallo L; Oliva R; Griffin M; Wang Z; Santoro C; Sblattero D
FASEB J; 2019 Feb; 33(2):2327-2342. PubMed ID: 30285580
[TBL] [Abstract][Full Text] [Related]
5. Enhanced osteoblast adhesion on transglutaminase 2-crosslinked fibronectin.
Forsprecher J; Wang Z; Nelea V; Kaartinen MT
Amino Acids; 2009 Apr; 36(4):747-53. PubMed ID: 18604470
[TBL] [Abstract][Full Text] [Related]
6. RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 α5β1 integrin co-signaling.
Wang Z; Collighan RJ; Gross SR; Danen EH; Orend G; Telci D; Griffin M
J Biol Chem; 2010 Dec; 285(51):40212-29. PubMed ID: 20929862
[TBL] [Abstract][Full Text] [Related]
7. Astrocyte-derived tissue transglutaminase interacts with fibronectin: a role in astrocyte adhesion and migration?
van Strien ME; Brevé JJ; Fratantoni S; Schreurs MW; Bol JG; Jongenelen CA; Drukarch B; van Dam AM
PLoS One; 2011; 6(9):e25037. PubMed ID: 21949843
[TBL] [Abstract][Full Text] [Related]
8. Tissue Tranglutaminase Regulates Interactions between Ovarian Cancer Stem Cells and the Tumor Niche.
Condello S; Sima L; Ivan C; Cardenas H; Schiltz G; Mishra RK; Matei D
Cancer Res; 2018 Jun; 78(11):2990-3001. PubMed ID: 29510995
[TBL] [Abstract][Full Text] [Related]
9. Transglutaminase 2 has higher affinity for relaxed than for stretched fibronectin fibers.
Selcuk K; Leitner A; Braun L; Le Blanc F; Pacak P; Pot S; Vogel V
Matrix Biol; 2024 Jan; 125():113-132. PubMed ID: 38135164
[TBL] [Abstract][Full Text] [Related]
10. Discovery and Characterization of PROTACs Targeting Tissue Transglutaminase (TG2).
Valdivia A; Vagadia PP; Guo G; O'Brien E; Matei D; Schiltz GE
J Med Chem; 2023 Jul; 66(14):9445-9465. PubMed ID: 37449845
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
Chrobok NL; Bol JGJM; Jongenelen CA; Brevé JJP; El Alaoui S; Wilhelmus MMM; Drukarch B; van Dam AM
PLoS One; 2018; 13(4):e0196433. PubMed ID: 29689097
[TBL] [Abstract][Full Text] [Related]
12. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
Yuan L; Siegel M; Choi K; Khosla C; Miller CR; Jackson EN; Piwnica-Worms D; Rich KM
Oncogene; 2007 Apr; 26(18):2563-73. PubMed ID: 17099729
[TBL] [Abstract][Full Text] [Related]
13. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells.
Herman JF; Mangala LS; Mehta K
Oncogene; 2006 May; 25(21):3049-58. PubMed ID: 16449978
[TBL] [Abstract][Full Text] [Related]
14. Transglutaminase 2: a novel therapeutic target for idiopathic pulmonary fibrosis using selective small molecule inhibitors.
Fell S; Wang Z; Blanchard A; Nanthakumar C; Griffin M
Amino Acids; 2021 Feb; 53(2):205-217. PubMed ID: 33474654
[TBL] [Abstract][Full Text] [Related]
15. Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer.
Yakubov B; Chelladurai B; Schmitt J; Emerson R; Turchi JJ; Matei D
Neoplasia; 2013 Jun; 15(6):609-19. PubMed ID: 23730209
[TBL] [Abstract][Full Text] [Related]
16. Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective small-molecule inhibitor.
Wang Z; Stuckey DJ; Murdoch CE; Camelliti P; Lip GYH; Griffin M
Cell Death Dis; 2018 Apr; 9(6):613. PubMed ID: 29795262
[TBL] [Abstract][Full Text] [Related]
17. Transglutaminase 2 strongly binds to an extracellular matrix component other than fibronectin via its second C-terminal beta-barrel domain.
Stamnaes J; Cardoso I; Iversen R; Sollid LM
FEBS J; 2016 Nov; 283(21):3994-4010. PubMed ID: 27685605
[TBL] [Abstract][Full Text] [Related]
18. Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase.
Satpathy M; Cao L; Pincheira R; Emerson R; Bigsby R; Nakshatri H; Matei D
Cancer Res; 2007 Aug; 67(15):7194-202. PubMed ID: 17671187
[TBL] [Abstract][Full Text] [Related]
19. Dissecting the interaction between transglutaminase 2 and fibronectin.
Cardoso I; Østerlund EC; Stamnaes J; Iversen R; Andersen JT; Jørgensen TJ; Sollid LM
Amino Acids; 2017 Mar; 49(3):489-500. PubMed ID: 27394141
[TBL] [Abstract][Full Text] [Related]
20. Appearance of tissue transglutaminase in astrocytes in multiple sclerosis lesions: a role in cell adhesion and migration?
van Strien ME; Drukarch B; Bol JG; van der Valk P; van Horssen J; Gerritsen WH; Breve JJ; van Dam AM
Brain Pathol; 2011 Jan; 21(1):44-54. PubMed ID: 20731658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
